ArtificialIntelligenceintheLifeSciences2(2022)100042
Contents lists available at ScienceDirect
Artificial Intelligence in the Life Sciences
journal homepage: www.elsevier.com/locate/ailsci
Research Article
An unsupervised computational pipeline identifies potential repurposable
drugs to treat Huntington’s disease and multiple sclerosis
Luca Menestrina, Maurizio Recanatini ∗
Department of Pharmacy and Biotechnology, Alma Mater Studiorum - University of Bologna, Via Belmeloro 6, 40126 Bologna, Italy
a r t i c l e i n f o a b s t r a c t
Keywords: Drug repurposing consists in identifying additional uses for known drugs and, since these new findings are built
Computational drug discovery on previous knowledge, it reduces both the length and the costs of the drug development. In this work, we
Drug repurposing assembled an automated computational pipeline for drug repurposing, integrating also a network-based analysis
Network pharmacology
for screening the possible drug combinations. The selection of drugs relies both on their proximity to the disease
Huntington’s disease
on the protein-protein interactome and on their influence on the expression of disease-related genes. Combined
Multiple sclerosis
therapies are then prioritized on the basis of the drugs’ separation on the human interactome and the known
drug-drug interactions. We eventually collected a number of molecules, and their plausible combinations, that
could be proposed for the treatment of Huntington’s disease and multiple sclerosis. Finally, this pipeline could
potentially provide new suggestions also for other complex disorders.
Introduction cal and experimental data [ 10 , 11 ], with a strategy for filtering all the
possible drug combinations [6] . Initially, the procedure estimates the
Discovering a new drug and bringing it to the market is a process proximity between the disease-related proteins and the drug targets on
both money and time consuming. Instead, relying on established drugs, the protein-protein interactome, performing a first selection of candi-
computational drug repositioning offers a valuable alternative approach dates. Then, only those drugs that significantly influence the expression
for providing promising treatments for disorders without a cure [ 1 , 2 ]. of disease-related genes are considered plausible for repurposing. Fi-
In recent years, a plethora of computational approaches to drug repur- nally, evaluating the separation of these drugs’ targets on the human
posing have been proposed and applied to a wide variety of therapeu- interactome and taking into consideration the known drug-drug inter-
tic areas [3] . Most of such approaches rely either on machine learn- actions, combined therapies are prioritized. The workflow of the pro-
ing or on the traditional methods of computational drug design, even cedure is schematically illustrated in Fig. 1 . The entire process is au-
though some conceptually innovative ideas have brought to the light tomated in order to reduce human intervention, thus accelerating the
the possibility of taking new paths towards the prediction of potentially whole procedure and limiting execution errors.
repurposable drugs. One of such ideas is based on a system view and We applied this pipeline to Huntington’s disease (HD) and multiple
takes the human protein-protein interactome as a reference network to sclerosis (MS) because, despite the fact that they are both neurologi-
quantify the relatedness between drugs and diseases by calculating the cal disorders, their different nature could represent a challenge for our
distance between drug targets and disease-associated proteins. This dis- strategy, and the outcomes could give us insights into its methodolog-
tance has been proposed as a suitable metrics to measure the "proximity" ical strengths and limitations. HD, is reported as a typical monogenic
between drugs and diseases [4] . Recently, leveraging on the concept of disease, even though many other genes are known to influence its pro-
drug-disease proximity [5] , novel drug indications for the treatment of gression [12] , while for MS a single genetic cause has not been found
cardiovascular diseases [ 5 , 6 ], cancers [7] , COVID-19 [8] , Alzheimer’s yet, probably because many factors play an important role in the etiol-
disease [9] have been proposed, demonstrating how a network-based ogy. Indeed, MS fits well the definition of complex disease to be consid-
approach could successfully assist the selection of drugs to be repur- ered in the framework of network medicine. On the other hand, HD was
posed. included in our study in order to test the capabilities of the proposed
In this work, we assembled an automated computational pipeline by method in a case where different clinical phenotypes might be related
integrating a recently developed scheme to screen repurposable drugs to a disease module eventually influenced by genetic modifiers leading
that combines a network-based technique with an analysis of biologi- to different pathophysiological states [12–14] .
∗ Corresponding author.
E-mail address: maurizio.recanatini@unibo.it (M. Recanatini) .
https://doi.org/10.1016/j.ailsci.2022.100042
Received 4 May 2022; Received in revised form 23 June 2022; Accepted 20 July 2022
Available online 27 July 2022
2667-3185/©2022 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
( http://creativecommons.org/licenses/by-nc-nd/4.0/ )L. Menestrina and M. Recanatini Artificial Intelligence in the Life Sciences 2 (2022) 100042
Fig. 1. Pipeline Flowchart. The flowchart shows the sources and the steps of the automated procedure to screen repurposable drug candidates and prioritize their
combinations.
HD is the most common monogenic neurological disorder. The on- computation of drug-disease proximity on the human protein-protein
set is typically in the early stage of adult life, and it is characterized interactome; (5) estimation of drug-induced gene expression signature
by motor dysfunction, cognitive impairment, and neuropsychiatric fea- enrichment; (6) calculation of drug-drug separation on the human in-
tures [ 12 , 15 ]. The autosomal dominant mutation that causes HD is lo- teractome. Except for the collection of the disease-related genes, each
cated in the HTT gene, and it consists in a cytosine-adenosine-guanine operation is performed by a Python 3 script, and the entire procedure is
trinucleotide repetition (CAG, encoding glutamine) leading to an over- brought together and coordinated by a main file in the same program-
expansion of the polyglutamine (polyQ) tail in the huntingtin protein. ming language.
The mutated protein tends to aggregate and accumulate, forming inclu-
sion bodies that have deleterious consequences for the neural cell. Both Collection of disease-related genes
the inclusion bodies and the length of the CAG expansion are proven
to play an important role in the development of the disease. The clear- For each of the two considered diseases, a set of related genes
ance of the first ones slows the HD progression, while the longer the was retrieved from KEGG [24] ( https://www.genome.jp/kegg/ ), OMIM
CAG expansion, the earlier the disease may manifest [15] . The remain- [25] ( https://www.omim.org/ ), PheGenI [26] ( https://www.ncbi.nlm.
ing uncertainty on the course of HD can be ascribed to other genetic nih.gov/gap/phegeni ), DISEASES [27] ( https://diseases.jensenlab.org/
differences in the genome of the patients [ 12 , 14 ]. search ), and DisGeNET [28] ( https://www.disgenet.org/ ).
MS is both the most frequent non-traumatic disabling disease in Briefly, for HD, 306 genes were retrieved from the KEGG Hunting-
young adults [16] and the commonest demyelinating disease [17] . The ton Disease pathway “hsa05016 ”; 152 querying OMIM for “Huntington
etiology and the mechanism causing its worsening progression are still Disease ”; 1 from the DISEASES database and 17 were those associated
unclear, nevertheless it has been proven that a complex interplay of ge- to “Huntington Disease ” on DisGeNET and having an Evidence Index
netic and environmental factors is important [ 18 , 19 ]. The main known ( https://www.disgenet.org/dbinfo#section36 ) of at least 0.95.
risk factors are smoking, childhood obesity, infection with the Epstein- On the other hand, for MS, 160 genes were the result of querying
Barr virus, and low vitamin D levels [19] . MS is generally viewed as a OMIM for “Multiple Sclerosis ”; 89 were collected from PheGenI with
two-phases autoimmune disease, in which initially focal inflammatory NHGRI (National Human Genome Research Institute) genome-wide as-
processes cause a relapsing-remitting form of the disease, and subse- sociation study as source and a p-value < 1 × 10 −8 ; 5 were retrieved
quently demyelinating plaques (lesions resulted by the previous immune from the DISEASES database; 30 gathered from DisGeNET with the same
response) and oligodendrocyte damage lead to neurodegeneration and conditions applied to HD.
non-relapsing progressive course [ 17 , 19 ]. MS is commonly character- The genes were mapped to official gene symbols taking advantage
ized by progressive spastic paraparesis, cognitive impairment, and sen- of the NCBI database and then combined.
sory and cerebellar dysfunctions[19].
Both HD and MS are still lacking resolutive treatments [ 20 , 21 ], Ontology (GO, HPO) enrichment analysis
whose development needs a deeper knowledge of the underlying mech-
anisms [22] . To this aim, network-based models, as the ones we utilized Functional enrichment analysis is often employed to perform a pre-
in this study, could be adequate theoretical tools for investigating such liminary analysis on an investigated gene set. Examining the Gene Ontol-
multifactorial disorders. They would allow us to take into account the ogy [29] (GO, http://geneontology.org/ ) and the Human Phenotype On-
latent complex structure of these diseases without losing a comprehen- tology [30] (HPO, https://hpo.jax.org/ ) associations, we gained insights
sive view [23] . Through the methodology presented here, we were able on biological processes, molecular functions, cellular components and
to collect a number of approved drugs and their plausible combinations phenotypes most frequently associated to those genes. We conducted
that could be proposed for the treatment of HD and MS. the functional enrichment analysis using the Python library GOATOOLS
[31] and considered significantly enriched only those terms with a false
Materials and methods discovery rate (FDR, p-value corrected for multiple comparisons using
the Benjamini-Hochberg procedure [32] ) lower than 1 ×10 −4 . We then
The workflow of this study can be outlined in the following steps looked at the first 20 terms ranked on the basis of their fold enrichment
( Fig. 1 ): (1) collection of disease-related genes; (2) gene sets validation (computed as the ratio of the percentage of genes in the study set re-
through enrichment analysis; (3) collection of drugs, targets, protein lated to a specific term, divided by the corresponding percentage in the
interaction data, and construction of protein-protein interactome; (4) background, i.e., the entire human proteome).
2L. Menestrina and M. Recanatini Artificial Intelligence in the Life Sciences 2 (2022) 100042
Drugs and targets collection, gene expression profiles retrieval and the distance 𝑑( 𝐺, 𝑇 ) between each drug and the disease was calculated
protein-protein interactome construction as:
∑
𝑑 ( 𝐺, 𝑇 ) = 1 min ( 𝑑 ( 𝑔, 𝑡 ) + 𝑤 ) (1)
Drugs information was collected from DrugBank [33] (version |𝑇 |
t∈𝑇
𝑔∈𝐺
5.1.9). Only those molecules having at least one human protein as target
where 𝑤 weights the targets based on their node degree in the interac-
are considered, obtaining 5 798 drugs and 2 755 corresponding targets.
tome ( 𝑤 = − ln( 𝐷 + 1) if the target is related to the disease, 𝑤 = 0 oth-
Drug-induced gene expression profiles were retrieved from the Li-
erwise). 𝐷is the degree of the target in the PPI network.
brary of Integrated Network-based Cellular Signatures [34] (LINCS, pro-
Then, for each drug, the significance of its association to the inves-
files “GSE70138 ” and “GSE92742 ”), downloaded from Gene Expres-
tigated disease was assessed comparing the measured distance to that
sion Omnibus [35] (GEO, http://www.ncbi.nlm.nih.gov/geo ). Due to
of a dummy reference distribution. This reference was obtained com-
the fact that we are inspecting neurological disorders, those signatures
puting 10 000 times the distance ( 𝑑( 𝐺, 𝑅) , defined by Eq. (1) ) between
tested on neural cell lines (NEU, NPC, SHSY5Y) were examined for both
the disease-related genes and randomly selected (from the human inter-
diseases. Additionally, in order to consider disease-specific features, also
actome) sets of proteins ( 𝑅 ) matching the number of the drug targets.
muscular cell lines (SKB, SKL) were included for HD, and haematopoi-
Since the degree of the drug targets is already taken into consideration
etic and lymphoid tissue cell lines (L60, JURKAT, NOMO1, PL21, SKM1,
in the distance calculation, the sampling of the randomly selected pro-
THP1, U937, WSUDLCL2) for MS. Furthermore, to guarantee maximum
teins is facilitated having to match only the number and not also the
reliability of the results, only the data about the Best Inferred Genes
(BING) in every dataset (drug signature) in these profiles was kept. The
degree distribution of the drug targets. The mean 𝜇 𝑑( 𝐺,𝑅) and standard
BING subset includes 978 landmark genes and 9 196 inferred genes,
deviation 𝜎 𝑑( 𝐺,𝑅) of the reference distribution were used to normalize
the observed distance into a proximity value (z-score):
which are identified among the 12 328 genes in the L1000 assay by
Subramanian et al. [36] evaluating the most reliable inference predic- 𝑧 ( 𝐺, 𝑇 ) = 𝑑 ( 𝐺, 𝑇 ) − 𝜇 𝑑 ( 𝐺,𝑅 ) (2)
𝜎
tions. 𝑑 ( 𝐺,𝑅 )
Extensive interactions among proteins are a key factor in accom-
plishing many biological processes and functions. For this reason, Inverted gene set enrichment analysis
we opted for a network-based approach to evaluate the correlation
between drugs and diseases or drugs and other drugs. We built a human Starting from the hypothesis that effective drugs should be able to
protein-protein interaction (PPI) network combining data from eight restore the healthy expression of genes deregulated by a disease, the
publicly available resources: Agile Protein Interactomes DataServer drugs with signatures most enriched in disease-related genes should also
[37] (APID, http://cicblade.dep.usal.es:8080/APID/init.action ), be the most promising ones in treating such disease. In order to gain this
Biological General Repository for Interaction Datasets [38] (Bi- knowledge, an Inverted Gene Set Enrichment Analysis [10] (IGSEA) on
oGRID, https://thebiogrid.org/ ), The Human Reference Interac- the datasets (drug signatures) of LINCS was performed, looking for the
tome [39] (HuRI, http://www.interactome-atlas.org/ ), InnateDB disease-related genes under study. For each analyzed dataset, the nor-
[40] ( https://www.innatedb.com/ ), INstruct [41] ( http://instruct. malized enrichment score and the p-value (estimated comparing the en-
yulab.org/ ), IntAct [42] ( https://www.ebi.ac.uk/intact/home ), Sig- richment score with those of a null distribution generated from 100 000
naLink [43] ( http://signalink.org/ ), and Search Tool for the Retrieval permutations) were computed for measuring the enrichment magnitude
of Interacting Genes/Proteins [44] (STRING, https://string-db.org/ ). and its statistical significance, respectively. The resulted p-values were
Supplementary Table 1 gives additional info about the interactions then corrected for multiple comparison using the Benjamini-Hochberg
reported in the databases and the applied filters. procedure [32] , obtaining the FDR. If the dataset was significantly en-
The retrieved interactions were then combined, obtaining a net- riched (FDR < 0.25), the corresponding drug was considered a potential
work (available in the Supplementary Information) consisting of 20 445 drug candidate.
nodes (genes/proteins) and 1 125 173 edges (interactions). Consistency
Network separation
is granted by the fact that all listed proteins are mapped to official
gene symbols taking advantage of the NCBI database. Since the protein-
An important aspect in investigating drug combinations is to eval-
protein interactome is the supporting pillar of the whole procedure, we
uate whether the two drug-target modules are overlapped (overlap-
assessed its validity comparing the results of the entire analyses based
ping exposure) or separated (complementary exposure) on the human
on two other interactomes. The first rerun was carried out on the widely
protein-protein interactome [6] . In the case of overlapping exposure,
recognized interactome from Cheng et al. [5] (16 677 unique proteins
there is a higher similarity in chemical, biological, functional, and clin-
and 243 603 experimentally confirmed protein–protein interactions).
ical profiles. The desired combinations, instead, are those with comple-
The second one was performed on a drastically restricted version of our
mentary exposure, both drugs being topologically and pharmacologi-
own interactome (16 954 proteins and 246 080 interactions), in which
cally distinct. In the latter case, the two drugs synergistically cooperate
only interactions from low throughput studies (listing less than 20 in-
in treating the disease, yet each one in its own way.
teractions) were included.
As we did for computing the drug-disease proximity, also for mea-
Network proximity suring drug-drug separation 𝑠 𝐴𝐵 in drug combinations, we employed a
network-based approach [ 6 , 45 ]:
throP ur go hte oi un ts thre el a inte ted
r
at co
t
oa
m
s ep ,e rc ai tfi hc
e
rd
,
i ts he ea ys e
te
a nr de
t
ou n gl ri ok ue ply
t
ot go
e
tb he
e
rs c foa rtt mer ined
g
𝑠
AB
= ⟨𝑑
AB
⟩−
⟨𝑑
AA
⟩+
2
⟨𝑑
BB
⟩
(3)
the so-called disease module [45] . The relationship between a drug and where 𝐴 is the target module of one drug and 𝐵that of the other. Here,
a disease could be estimated by means of an unsupervised and unbiased the mean shortest distances (calculated with Eq. (1) with the weight 𝑤
network-based approach [4] , which quantifies the interplay of drug tar- fixed to 0) between the target modules of each drug ( ⟨𝑑 𝐴𝐴 ⟩and ⟨𝑑 𝐵𝐵 ⟩,
gets and disease-related genes measuring a network proximity. Here we computable only for drugs with at least two targets) are compared to
used a recently modified version of such method [10] that includes a the mean shortest distance between all possible A-B target pairs ( ⟨𝑑 𝐴𝐵 ⟩).
term ( 𝑤 ) for taking into account the degree of the drug targets directly When computing the distances between A-B target pairs, if a protein is
into the distance calculation. Given 𝐺, the set of disease-related genes; targeted by both drugs, its distance is zero by definition. A drug combi-
𝑇 , the set of drug targets; and 𝑑( 𝑔, 𝑡) , the shortest path length between nation exposure is deemed complementary if 𝑠 𝐴𝐵 ≥ 0 , overlapping oth-
nodes 𝑔( 𝑔 ∈𝐺) and 𝑡 ( 𝑡 ∈𝑇 ) in the human protein-protein interactome; erwise.
3L. Menestrina and M. Recanatini Artificial Intelligence in the Life Sciences 2 (2022) 100042
Fig. 2. Enriched Biological Processes. The bubbleplots display the top 20 most enriched Gene Ontology terms relative to biological processes for Huntington’s disease
(A) and multiple sclerosis (B). On the horizontal axis, the fold enrichment is shown. The color encodes the negative of the false discovery rate logarithm, and the
size represents the gene ratio (computed as the ratio of the percentage of genes in the study set related to a specific term, divided by the corresponding percentage
in the background, i.e., the entire human proteome).
Results respectively. In order to evaluate whether these genes were representa-
tive of the investigated diseases, we performed an enrichment analysis
Computational framework on GO and HPO terms. This allowed us to check if the most enriched
biological processes, molecular functions, cellular components and phe-
In this study, we automated the pipeline shown in Fig. 1 for screening notypes were in accordance with previous knowledge.
repurposable drug candidates and prioritizing their combinations. In or- Prior studies relate HD to dysfunctions in transcription, intracellular
der to run, the script only requires the disease name, the disease-related signaling, intracellular transport, endocytic recycling, and mitochondria
genes, and the cell lines of interest as inputs. This procedure consists [12] . This knowledge is consistent with the biological processes, cellu-
of: collecting, cleaning and organizing the source data (disease-related lar components and molecular functions that we found to be enriched
genes, drugs, targets, protein interactions, drug-induced gene expres- ( Fig. 2 A and Supplementary Figure 1 A, B). The same holds for the phe-
sion signatures); identifying repurposable drug candidates evaluating notypes, which are associated to negativism, social and occupational
both their proximity to the disease and their effect on the expression of deterioration, mitochondrial and nervous issues (Supplementary Figure
the disease-related genes; screening the possible drug combinations on 1 C) [ 12 , 15 ].
the basis of their relative exposure and known interactions. The output MS is an autoimmune disorder whose inflammatory infiltrates con-
of the routine is a collection of tables (tab-separated values files) and tain T-lymphocytes and B-cells, and leads to oligodendrocyte damage
plots, recording both intermediate and final results. and demyelination [19] . This is coherent with the enriched terms in our
Compared to previous related works [ 10 , 11 ], such a systematic strat- analysis ( Fig. 2 B and Supplementary Figure 2).
egy should be more efficient and have an improved reproducibility The fact that the obtained results were confirmed by the literature
thanks to the organization and standardization of both the overall study suggested that the gathered genes were representative of the diseases
and results. Additionally, it takes a step forward since it evaluates also under study.
possible combined therapies. Furthermore, as in Menche et al. [45] , the disease modules were
The single steps and the outcomes of the application of the frame- tested to be nonrandom gene aggregates. The size of the largest con-
work to HD and MS are presented and discussed in the follow- nected component of the disease module was compared to the size of
ing. the one obtained by randomly picking the proteins (matching the num-
ber of the disease-related genes) from the interactome (the comparison
Disease-related genes collection and validation is shown in Supplementary Figure 3). For both diseases, the disease mod-
ule resulted to be significantly larger than the random counterpart, al-
We gathered the disease-related genes as described in the Methods lowing us to state that they cannot be attributed to a casual aggregation
section: this resulted in 451 and 217 genes associated to HD and MS, of genes.
4L. Menestrina and M. Recanatini Artificial Intelligence in the Life Sciences 2 (2022) 100042
Fig. 3. Distance Distributions. The distribution of the distance between drug targets and disease-related proteins (solid blue line) compared to that of a reference
collection (dashed orange line), for Huntington’s disease (A) and multiple sclerosis (B). On the vertical axis, the kernel density estimation of the distribution is shown.
The plot is divided into two parts by the chosen distance threshold (green line, see Methods).
Repurposable drugs selection To be more confident on the pool of predicted repurposable drugs,
we replicated the entire procedure using three different interactomes.
The network-based proximity analysis, leveraging on the potential Our original one and the two networks used to validate it differ both in
of a system view, could suggest valuable drugs able to interfere with size and in listed interactions (see Methods). Despite these differences,
the disease molecular determinants in a non-trivial way (i.e., not only the repurposable drug sets suggested for both investigated diseases re-
directly targeting disease-related genes). The idea behind this method sulted fairly consistent. In the case of HD, 138 drugs were prioritized
is that drugs proximal to the disease module should be more effec- based on the original interactome, 110 on Cheng’s one, 133 on our re-
tive than distant ones, as shown by Guney et al. in an extensive anal- stricted interactome. It is noteworthy that all the molecules retrieved
ysis that considered known diseases and disease-associated genes, as from the two smaller interactomes are included among those of the first
well as drugs and their targets [4] . Following Peng’s protocol [10] , one. A very similar conclusion could be drawn for MS, for which the pro-
the procedure compares the distribution of the distances between drug cedure predicted 39 drugs with the large interactome, 26 with Cheng’s
targets and disease-related proteins to that of a reference collection one, and 29 with the severely constrained version of our interactome.
(see Methods and Fig. 3 ). For both diseases, it was possible to iden-
tify a distance value below which the two density curves (drugs and Drug combinations
reference) drop dramatically. In particular, the reference density as-
sumes negligible values for distances below this point ( Fig. 3 , green Combined therapies and multi-targeted agents have proven to offer
part of the plot). We elected such distance value ( Fig. 3 , vertical significant advantages over monotherapy, presenting higher efficacies
green line) as the threshold to discriminate drugs associated to the dis- and less adverse reactions [ 6 , 46 ]. Due to combinatorial explosion, how-
eases. These distances are 0.68 and 0.71 (corresponding to proximity: ever, it is generally not feasible to test all theoretically possible asso-
−0 .53 and –0.98) for HD and MS, respectively. From this analysis, 685 ciations. For this reason, we adopted a recent methodology proposed
(11.8%) out of the 5798 drugs collected from DrugBank were consid- by Cheng et al. [6] , which is based on the estimation of target neigh-
ered significantly proximal medicaments for HD, and 475 (8.2%) for borhoods separation on the human protein-protein interactome. Taking
MS. advantage of that, the investigated combinations may be screened on
In order to evaluate the impact of a drug on the disease, we examined the basis of the pharmacological relationship between drugs (see Meth-
the effect of its administration on the expression of the disease-related ods). Additionally, we looked in DrugBank for approved associations
genes in relevant cell lines (see Methods). We pursued this objective and interactions that increase the risk or severity of adverse effects. In
by performing an Inverted Gene Set Enrichment Analysis (IGSEA) on this way, we ended up having an assortment of plausible combinations
896 drugs, observed in 6 212 LINCS expression datasets for HD and 960 listed in Supplementary Tables 4, 5 and identifiable in the annotated
drugs in 5 579 datasets for MS. This analysis resulted in 843 and 600 heatmaps of Fig. 5 for HD and of Supplementary Figure 5 for MS.
significantly enriched drugs, for HD and MS respectively.
The drugs that were both significantly enriched and proximal to Discussion
the disease were deemed to be repurposable drug candidates: 138 for
HD and 38 for MS (Supplementary Tables 2, 3). The interactions be- Protein-Protein interactomes
tween the MS-related-genes, the drug targets, and the repurposable drug
candidates are visualized in Fig. 4 (and Supplementary Figure 4 for For both diseases, the repurposable drug pools predicted using the
HD), showing how drugs can be related to the disease through their three interactomes are in reasonable concordance. However, it is signif-
targets. icant that the execution of the pipeline on our interactome, compared
Unfortunately, only a small portion of the proximal drugs has data to the same procedure on Cheng’s interactome, improves the prediction
in the LINCS database (21.9% for HD and 13.7% for MS). Even though adding 7 drugs with evidence from clinical trials, 9 from in vivo studies,
the IGSEA analysis increases the reliability of the results, it dramatically 1 from in vitro experiments for HD, and 5 clinically tested drugs and 1
reduces the number of molecules that can be investigated and possibly investigated in an animal model for MS.
proposed. This has to be taken into account when evaluating the out- This outcome seems to suggest that injecting more input data in
comes of the study. the procedure (still maintaining high reliability standards) leads to in-
5L. Menestrina and M. Recanatini Artificial Intelligence in the Life Sciences 2 (2022) 100042
Fig. 4. Multiple Sclerosis Gene-Target-Drug Network. The Sankey diagram illustrates the interconnections between disease-related genes, drug targets, and drugs.
Each drug (right column) is connected to its reported targets (middle column), which, in turn, are proximal on the human interactome to some of the disease-associated
proteins (left column). Drugs are colored by the respective ATC code, and the FDR of the IGSEA analysis (see Methods) is reported in the label.
creased performance, which is perfectly in line with the Big Data per- ples being selisistat [48] , lisuride [49] , valproic acid [50] , and risperi-
spective [47] . done [20] .
Selisistat was found to be safe, well tolerated, and capable of reach-
Repurposable drugs ing a plasma concentration compatible with the SirT1 inhibition, which
has been shown to restore transcriptional dysregulation in models of HD
Among the drugs selected to tackle HD (138), several (17) have been [48] . Lisuride is able to induce a temporary yet significant improvement
clinically tested and suggested, many show strong evidence from in vivo in the motor performance of patients with hyperkinesia caused by HD
tests (35) or promising results from in vitro assays (9). All the references [49] . Valproic acid was shown to be a possible alternative treatment for
are reported in the Supplementary Table 2, the most noticeable exam- HD patients suffering from myoclonic hyperkinesia [50] . Risperidone
6L. Menestrina and M. Recanatini Artificial Intelligence in the Life Sciences 2 (2022) 100042
Fig. 5. Huntington’s Disease Drug Combinations. The annotated heatmap provides info about possible combinations of the selected drugs. A combination is marked
with ×if an interaction is reported in DrugBank, and with ○if it is present in an approved formulation. The lower-left part of the heatmap shows the separation
of the inspected drugs, color coded from blue (no separation) to red (strongly separated). The upper-right portion, instead, displays the kind of exposure: violet if
overlapping and green if complementary. At the leftmost part, the ATC codes of the drugs are reported along with a dendrogram of their hierarchical clustering.
has beneficial effects in the treatment of psychiatric manifestations and of the drugs in clinical trials aim to alleviate the symptoms, while the
stabilization of motor symptoms in patients with HD [20] . only one we found to be capable of reducing relapses is Escitalopram
Inspecting the drugs screened for MS (38), we obtained a comparable [51] for which there is evidence suggesting it may be an effective and
outcome: 7 of them are clinically studied and 9 experimented on animal well-tolerated treatment for preventing stress-related relapses in women
models. All the evidence is listed in the Supplementary Table 3. Most with MS [51] .
7L. Menestrina and M. Recanatini Artificial Intelligence in the Life Sciences 2 (2022) 100042
Examining the Anatomical Therapeutic Chemical (ATC) codes of the highlight that drugs that do not have ATC codes associated to them are
repurposable drugs, the first thing to notice is the predictable preva- also those with few (or nothing at all) reported interactions. This sug-
lence of drugs associated to the ATC code N (Nervous System) for both gests that they are not sufficiently characterized and additional studies
diseases. Apart from this, the most common codes for HD repurposable on them are needed before further consideration.
drugs are C (Cardiovascular) and L (Antineoplastic and Immunomodu- The collected plausible combinations are numerous, but the associ-
lating Agents). The first group is mainly represented by statins, used to ation of orphenadrine (DB01173) and caffeine (DB00201) for HD de-
cope with the cholesterol impairment typical of HD patients [52] . The serves to be highlighted. These molecules are present along with acetyl-
immunomodulating agents are principally immunosuppressants and hi- salicylic acid (ASA) in an FDA approved formulation for muscular pain
stone deacetylases inhibitors, the last ones aimed at recovering from the relief. This medication is noteworthy for many reasons. First of all,
histone hypoacetylation common in neurological disorders [53] . pain is a known issue in HD and could be an important non-motor
For MS, instead, the second most frequent code is L (Antineoplastic symptom [ 59 , 60 ] thus, its treatment should not be neglected. Further-
and Immunomodulating Agents). Some relevant examples are ruxoli- more, orphenadrine showed to be effective in preventing neurotoxicity
tinib, paclitaxel, tamoxifen, and thalidomide, which are capable of at- in rats with a chemically-induced condition that mimics the histologi-
tenuating experimental autoimmune encephalomyelitis and of inducing cal and neurochemical features of HD [61] . Additionally, low dosages
remyelination [54–58] . of caffeine showed to be beneficial in HD animal models [62] . Finally,
ASA was included in the formulation for relieving pain and decreasing
Drug combinations swelling. Even though ASA was proximal to HD, it was not included in
our results because its data was not available in LINCS for the investi-
Observing the obtained results (depicted as annotated heatmaps in gated cell lines. However, it is actually profitable for the present aim,
Fig. 5 for HD and Supplementary Figure 5 for MS) it is interesting to since it showed to prevent protein aggregation in several neurodegen-
Fig. 6. Escitalopram and Tofacitinib Comple-
mentary Exposure. The network displays the
proteins associated to MS (circles) and high-
lights those targeted by escitalopram and tofac-
itinib (dark green and dark blue, respectively).
Targets that are not related to MS are indicated
as triangles. In order to better illustrate the in-
fluence of these two molecules given by the
tight interconnection of the proteome, the first
neighbors of the drug targets are depicted in
a lighter color (light green for neighbors of tar-
gets of escitalopram, and light blue tofacitinib’s
ones).
8L. Menestrina and M. Recanatini Artificial Intelligence in the Life Sciences 2 (2022) 100042
erative diseases [63] . Further assessments are needed, but this could be of the distance threshold we use for discriminating drug efficacy is quite
an interesting point where to start. discretionary.
A reasonable hypothesis for treating MS might be an association
of two drugs sufficiently separated from each other as escitalopram Conclusions
(DB01175) and tofacitinib (DB08895) or ruxolitinib (DB08877), capa-
ble of affecting complementary parts of the disease module. Fig. 6 shows Here, we extended an unsupervised computational framework for
the network of the interactions among proteins associated to MS (all cir- drug repurposing with a network-based analysis for screening the pos-
cles) and highlights those targeted by escitalopram and tofacitinib (dark sible drug combination therapies. Applying this pipeline to HD and MS,
green and dark blue, respectively). Among these targets, two of them, we identified several repurposable drug candidates, some of which have
namely HRH1 for escitalopram (dark green circle) and TYK2 for tofac- already been studied in humans. Eventually, we ended up with 138 po-
itinib (dark blue circle), belong to the MS disease module, while those tential drugs for HD and 38 for MS. Their plausible combinations are
that are not directly related to MS are depicted as triangles (maintain- numerous, but this work can help to prioritize them. While these re-
ing the same color coding). In order to better illustrate the influence on sults are exploratory and should be experimentally verified before fur-
the disease module of the two drugs in terms of protein-protein inter- ther consideration, they could provide valuable clues for improving the
actions, the first neighbors of the drug targets are colored lighter (light management of HD and MS.
green for neighbors of targets of escitalopram, and light blue for tofaci- Finally, this pipeline demonstrated to be effective on both investi-
tinib’s ones). It can be seen that overall the targets of both escitalopram gated diseases, even though they have a different nature. For this rea-
and tofacitinib or their first neighbors can influence a reasonable part of son, it could potentially provide new suggestions also for other complex
the disease module without redundantly interfering with the same MS disorders.
proteins. In fact, our analysis showed that these drugs are proximal to
MS and significantly influence proteins associated to this disease. Addi- Data and code availability
tionally, no interactions between them have been reported in DrugBank.
Moreover, we found experimental evidence supporting this inference. The most relevant results are included in this article (and its supple-
Escitalopram is a selective serotonin re-uptake inhibitor (ATC code: N, mentary information files). The whole generated data is publicly avail-
Nervous) that in humans proved to prevent stress-related relapses [51] . able from the GitHub repository https://github.com/LucaMenestrina/
Tofacitinib and ruxolitinib showed promising effects in animal models: UnsupervisedComputationalFrameworkForDrugRepurposing , as well as
the first one enhancing remyelination and improving myelin integrity the full code for the collection, building and analysis. A detailed ref-
[64] , and the second one ameliorating the severity of the disease [54] . erence of the source data is provided in the file “data/sources/sources.
Furthermore, they are Janus kinase (JAK) inhibitors (ATC code: L, Anti- json ”of the aforementioned repository (for every database are reported:
neoplastic and Immunomodulating Agents) and the JAK/STAT pathway name, version, license, employed files, URL and date of access).
is aberrantly activated in MS [ 21 , 65 ].
In the other drug combinations, which are sufficiently separated (see Declaration of Competing Interest
Methods, green on the heatmaps) and for which no adverse interactions
are reported (not annotated with an ×in the heatmaps), valuable clues The authors declare no competing interests.
for polypharmacological interventions could be found. A working hy-
pothesis might be to choose two drugs tackling different aspects of a Funding
disease, for instance featuring distinct ATC codes.
This research received no specific grant from any funding agency in
the public, commercial, or not-for-profit sectors.
Limitations
Supplementary materials
Despite our best efforts, this study is not exempt from some short-
comings that are common in data analysis, and regard mainly the data Supplementary material associated with this article can be found, in
availability and quality. This could have led us to miss some promis- the online version, at doi:10.1016/j.ailsci.2022.100042 .
ing compounds and, at the same time, it may compromise some of the
analyses. References
A complete characterization of all available drugs and human pro-
teins is surely not at hand, and this has repercussions on many aspects [1] Pushpakom S, Iorio F, Eyers PA, et al. Drug repurposing: progress, challenges and
recommendations. Nat Rev Drug Discov 2018;18:41–58. doi: 10.1038/nrd.2018.168 .
of the study, like, e.g., the human protein-protein interactome con-
[2] Talevi A, Bellera CL. Challenges and opportunities with drug repurposing: find-
struction, drug association to biological processes, cellular components, ing strategies to find alternative uses of therapeutics. Expert Opin Drug Discov
molecular functions and phenotypes, and drug induced gene expression 2020;15:397–401. doi: 10.1080/17460441.2020.1704729 .
[3] Choudhury C, Arul Murugan N, Priyakumar UD. Structure-based drug repurpos-
profiles retrieval. Only sometimes, this issue could be partially mitigated
ing: traditional and advanced AI/ML-aided methods. Drug Discov Today 2022.
by an extensive integration of data from a wider variety of databases. doi: 10.1016/j.drudis.2022.03.006 .
Noteworthy, puzzling examples could be the drug-target association and [4] Guney E, Menche J, Vidal M, Barábasi AL. Network-based in silico drug efficacy
the availability of expression data in LINCS. The number of targets as-
screening. Nat Commun 2016;7:10331. doi: 10.1038/ncomms10331 .
[5] Cheng F, Desai RJ, Handy DE, et al. Network-based approach to prediction
sociated to a specific drug could considerably depend on the amount and population-based validation of in silico drug repurposing. Nat Commun
of research carried out on that medicine rather than on the actual bi- 2018;9:2691. doi: 10.1038/s41467-018-05116-5 .
ological interactions it has. This influences the drug-disease proximity [6] Cheng F, Kovács IA, Barabási AL. Network-based prediction of drug combinations.
Nat Commun 2019;10:1197. doi: 10.1038/s41467-019-09186-x .
evaluation. Additionally, as stated above, the LINCS database does not [7] Cheng F, Lu W, Liu C, et al. A genome-wide positioning systems net-
provide expression profiles for all the drugs selected by network prox- work algorithm for in silico drug repurposing. Nat Commun 2019;10:3476.
imity, limiting by far the choice space for drug repurposing. doi: 10.1038/s41467-019-10744-6 .
[8] Zhou Y, Hou Y, Shen J, et al. A network medicine approach to investigation and
Furthermore, if the knowledge we have about drugs is incomplete,
population-based validation of disease manifestations and drug repurposing for
the one we have on their combination is even sparser. This, obviously, COVID-19. PLOS Biol 2020;18:e3000970. doi: 10.1371/JOURNAL.PBIO.3000970 .
affects our ability to screen and judge plausible associations. [9] Fang J, Zhang P, Zhou Y, et al. Endophenotype-based in silico network
medicine discovery combined with insurance record data mining identifies silde-
Moreover, it could be argued that, even though the drug-disease
nafil as a candidate drug for Alzheimer’s disease. Nat Aging 2021;1:1175–88.
proximity is evaluated with a rigorous geometrical approach, the choice doi: 10.1038/s43587-021-00138-z .
9L. Menestrina and M. Recanatini Artificial Intelligence in the Life Sciences 2 (2022) 100042
[10] Peng Y, Yuan M, Xin J, Liu X, Wang J. Screening novel drug candidates for [40] Breuer K, Foroushani AK, Laird MR, et al. InnateDB: systems biology of innate im-
Alzheimer’s disease by an integrated network and transcriptome analysis. Bioinfor- munity and beyond - Recent updates and continuing curation. Nucleic Acids Res
matics 2020;36:4626–32. doi: 10.1093/bioinformatics/btaa563 . 2013;41:D1228–33. doi: 10.1093/nar/gks1147 .
[11] Quan P, Wang K, Yan S, et al. Integrated network analysis identifying potential [41] Meyer MJ, Das J, Wang X, Yu H. INstruct: a database of high-quality 3D struc-
novel drug candidates and targets for Parkinson’s disease. Sci Rep 2021;11:13154. turally resolved protein interactome networks. Bioinformatics 2013;29:1577–9.
doi: 10.1038/s41598-021-92701-2 . doi: 10.1093/bioinformatics/btt181 .
[12] Bates GP, Dorsey R, Gusella JF, et al. Huntington disease. Nat Rev Dis Prim [42] Orchard S, Ammari M, Aranda B, et al. The MIntAct project - IntAct as a com-
2015;1:15005. doi: 10.1038/nrdp.2015.5 . mon curation platform for 11 molecular interaction databases. Nucleic Acids Res
[13] Loscalzo J, Kohane I, Barabasi AL. Human disease classification in the postgenomic 2014;42:D358–63. doi: 10.1093/nar/gkt1115 .
era: a complex systems approach to human pathobiology. Mol Syst Biol 2007;3:124. [43] Csabai L, Fazekas D, Kadlecsik T, et al. SignaLink3: a multi-layered resource to
doi: 10.1038/MSB4100163 . uncover tissue-specific signaling networks. Nucleic Acids Res 2022;50:D701–9.
[14] Wright GEB, Black HF, Collins JA, et al. Interrupting sequence variants and age of doi: 10.1093/nar/gkab909 .
onset in Huntington’s disease: clinical implications and emerging therapies. Lancet [44] Szklarczyk D, Gable AL, Lyon D, et al. STRING v11: protein-protein as-
Neurol 2020;19:930–9. doi: 10.1016/S1474-4422(20)30343-4 . sociation networks with increased coverage, supporting functional discovery
[15] Finkbeiner S, disease Huntington’s. Cold Spring Harb Perspect Biol 2011;3:a007476. in genome-wide experimental datasets. Nucleic Acids Res 2019;47:D607–13.
doi: 10.1101/cshperspect.a007476 . doi: 10.1093/nar/gky1131 .
[16] Kobelt G, Thompson A, Berg J, Gannedahl M, Eriksson J. New insights into the [45] Menche J, Sharma A, Kitsak M, et al. Uncovering disease-disease relationships
burden and costs of multiple sclerosis in Europe. Mult Scler 2017;23:1123–36. through the incomplete interactome. Science 2015;347:1257601. doi: 10.1126/sci-
doi: 10.1177/1352458517694432 . ence.1257601 .
[17] Leray E, Moreau T, Fromont A, Edan G. Epidemiology of multiple sclerosis. Rev [46] Jia J, Zhu F, Ma X, et al. Mechanisms of drug combinations: interaction and network
Neurol (Paris) 2016;172:3–13. doi: 10.1016/j.neurol.2015.10.006 . perspectives. Nat. Rev. Drug Discov. 2009;8:111–28. doi: 10.1038/nrd2683 .
[18] Ramagopalan SV, Dobson R, Meier UC, Giovannoni G. Multiple sclerosis: risk fac- [47] Zhu H. Big data and artificial intelligence modeling for drug discovery.
tors, prodromes, and potential causal pathways. Lancet Neurol 2010;9:727–39. Annu Rev Pharmacol Toxicol 2020;60:573–89. doi: 10.1146/annurev-pharm-
doi: 10.1016/S1474-4422(10)70094-6 . tox-010919-023324 .
[19] Dobson R, Giovannoni G. Multiple sclerosis –a review. Eur J Neurol 2019;26:27–40. [48] Süssmuth SD, Haider S, Landwehrmeyer GB, et al. An exploratory double-blind, ran-
doi: 10.1111/ene.13819 . domized clinical trial with selisistat, a SirT1 inhibitor, in patients with Huntington’s
[20] DuffK, Beglinger LJ, O’Rourke ME, et al. Risperidone and the treatment of psychi- disease, Br. J Clin Pharmacol 2015;79:465–76. doi: 10.1111/bcp.12512 .
atric, motor, and cognitive symptoms in Huntington’s disease. Ann Clin Psychiatry [49] Frattola L, Albizzati MG, Alemani A, et al. Acute treatment of Huntington’s chorea
2008;20:1–3. doi: 10.1080/10401230701844802 . with lisuride. J Neurol Sci 1983;59:247–53. doi: 10.1016/0022-510X(83)90042-4 .
[21] Hamid KM, Isiyaku A, Kalgo MU, Yahaya IS, Mirshafiey A, Lodges in JAK-STAT. [50] Saft C, Lauter T, Kraus PH, Przuntek H, Andrich JE. Dose-dependent improvement of
Multiple sclerosis: pathophysiology and therapeutic approach overview. Open Ac- myoclonic hyperkinesia due to valproic acid in eight Huntington’s Disease patients:
cess Libr J 2017;4:e3492. doi: 10.4236/oalib.1103492 . a case series. BMC Neurol 2006;6:11. doi: 10.1186/1471-2377-6-11 .
[22] Gitler AD, Dhillon P, Shorter J. Neurodegenerative disease: models, mechanisms, and [51] Mitsonis CI, Zervas IM, Potagas CM, et al. Effects of escitalopram on stress-
a new hope. DMM Dis Model Mech 2017;10:499–502. doi: 10.1242/dmm.030205 . related relapses in women with multiple sclerosis: an open-label, randomized,
[23] Recanatini M, Cabrelle C. Drug research meets network science: where are we? J controlled, one-year follow-up study. Eur Neuropsychopharmacol 2010;20:123–31.
Med Chem 2020;63:8653–66. doi: 10.1021/acs.jmedchem.9b01989 . doi: 10.1016/j.euroneuro.2009.10.004 .
[24] Kanehisa M, Furumichi M, Tanabe M, Sato Y, Morishima K. KEGG: new perspectives [52] Karasinska JM, Hayden MR. Cholesterol metabolism in Huntington disease. Nat Rev
on genomes, pathways, diseases and drugs. Nucleic Acids Res 2017;45:D353–61. Neurol 2011;7:561–72. doi: 10.1038/nrneurol.2011.132 .
doi: 10.1093/nar/gkw1092 . [53] Shukla S, Tekwani BL. Histone deacetylases inhibitors in neurodegenerative dis-
[25] Amberger JS, Bocchini CA, Scott AF, Hamosh A. OMIM.org: leveraging knowl- eases, neuroprotection and neuronal differentiation. Front Pharmacol 2020;11:537.
edge across phenotype-gene relationships. Nucleic Acids Res 2019;47:D1038–43. doi: 10.3389/FPHAR.2020.00537/BIBTEX .
doi: 10.1093/nar/gky1151 . [54] Hosseini A, Gharibi T, Mohammadzadeh A, et al. Ruxolitinib attenuates experimen-
[26] Ramos EM, Hoffman D, Junkins HA, et al. Phenotype-genotype integrator (PheGenI): tal autoimmune encephalomyelitis (EAE) development as animal models of multiple
synthesizing genome-wide association study (GWAS) data with existing genomic sclerosis (MS). Life Sci 2021;276:119395. doi: 10.1016/j.lfs.2021.119395 .
resources. Eur J Hum Genet 2014;22:144–7. doi: 10.1038/ejhg.2013.96 . [55] Moscarello MA, Mak B, Nguyen TA, et al. Paclitaxel (Taxol) attenuates clinical dis-
[27] Pletscher-Frankild S, Pallejà A, Tsafou K, Binder JX, Jensen LJ. DISEASES: text ease in a spontaneously demyelinating transgenic mouse and induces remyelination.
mining and data integration of disease-gene associations. Methods 2015;74:83–9. Mult Scler J 2002;8:130–8. doi: 10.1191/1352458502ms776oa .
doi: 10.1016/j.ymeth.2014.11.020 . [56] Gonzalez GA, Hofer MP, Syed YA, et al. Tamoxifen accelerates the repair
[28] Piñero J, Ramírez-Anguita JM, Saüch-Pitarch J, et al. The DisGeNET knowledge of demyelinated lesions in the central nervous system. Sci Rep 2016;6:1–13.
platform for disease genomics: 2019 update. Nucleic Acids Res 2020;48:D845–55. doi: 10.1038/srep31599 .
doi: 10.1093/nar/gkz1021 . [57] Rankin KA, Mei F, Kim K, et al. Selective estrogen receptor modulators enhance
[29] Carbon S, Douglass E, Good BM, et al. The Gene Ontology resource: enriching a GOld cns remyelination independent of estrogen receptors. J Neurosci 2019;39:2184–94.
mine. Nucleic Acids Res 2021;49:D325–34. doi: 10.1093/nar/gkaa1113 . doi: 10.1523/JNEUROSCI.1530-18.2019 .
[30] Köhler S, Gargano M, Matentzoglu N, et al. The human phenotype ontology in 2021. [58] Contino-Pépin C, Parat A, Patinote C, et al. Thalidomide derivatives for
Nucleic Acids Res 2021;49:D1207–17. doi: 10.1093/nar/gkaa1043 . the treatment of neuroinflammation. ChemMedChem 2010;5:2057–64.
[31] Klopfenstein DV, Zhang L, Pedersen BS, et al. GOATOOLS: a python library for gene doi: 10.1002/CMDC.201000326 .
ontology analyses. Sci Rep 2018;8:10872. doi: 10.1038/s41598-018-28948-z . [59] Underwood M, Bonas S, Dale M, Disease Huntington’s. Prevalence and
[32] Benjamini Y, Hochberg Y. Controlling the false discovery rate: a practical and psychological indicators of pain. Mov Disord Clin Pract 2017;4:198–204.
powerful approach to multiple testing. J. R. Stat. Soc. Ser. B. 1995;57:289–300. doi: 10.1002/MDC3.12376 .
doi: 10.1111/j.2517-6161.1995.tb02031.x . [60] Sprenger GP, Roos RAC, van Zwet E, et al. The prevalence of pain in Hunt-
[33] Wishart DS, Feunang YD, Guo AC, et al. DrugBank 5.0: a major update ington’s disease in a large worldwide cohort. Park Relat Disord 2021;89:73–8.
to the DrugBank database for 2018. Nucleic Acids Res 2018;46:D1074–82. doi: 10.1016/j.parkreldis.2021.06.015 .
doi: 10.1093/nar/gkx1037 . [61] Pubill D, Verdaguer E, Canudas AM, et al. Orphenadrine prevents 3-nitropropionic
[34] Lamb J, Crawford ED, Peck D, et al. The connectivity map: using gene-expression acid-induced neurotoxicity in vitro and in vivo. Br J Pharmacol 2001;132:693–702.
signatures to connect small molecules, genes, and disease. Science 2006;313:1929– doi: 10.1038/sj.bjp.0703869 .
35. doi: 10.1126/science.1132939 . [62] Kolahdouzan M, Hamadeh MJ. The neuroprotective effects of caffeine in neurode-
[35] Barrett T, Wilhite SE, Ledoux P, et al. NCBI GEO: archive for functional genomics generative diseases. CNS Neurosci Ther 2017;23:272–90. doi: 10.1111/cns.12684 .
data sets - Update. Nucleic Acids Res 2013;41:D991–5. doi: 10.1093/nar/gks1193 . [63] Ayyadevara S, Balasubramaniam M, Kakraba S, et al. Aspirin-mediated acetylation
[36] Subramanian A, Narayan R, Corsello SM, et al. A next generation connectivity protects against multiple neurodegenerative pathologies by impeding protein aggre-
map: L1000 platform and the first 1,000,000 profiles. Cell 2017;171:1437–52. gation. Antioxidants Redox Signal 2017;27:1383–96. doi: 10.1089/ars.2016.6978 .
doi: 10.1016/j.cell.2017.10.049 . [64] Günayd ı n C, Önger ME, Avc ı B, et al. Tofacitinib enhances remyelination and im-
[37] Alonso-López Di, Campos-Laborie FJ, Gutiérrez MA, et al. APID database: redefin- proves myelin integrity in cuprizone-induced mice. Immunopharmacol Immunotox-
ing protein-protein interaction experimental evidences and binary interactomes. icol 2021;43:790–8. doi: 10.1080/08923973.2021.1986063 .
Database 2019;2019:baz005. doi: 10.1093/database/baz005 . [65] Benveniste EN, Liu Y, McFarland BC, Qin H. Involvement of the Janus kinase/signal
[38] Oughtred R, Rust J, Chang C, et al. The BioGRID database: a comprehensive biomed- transducer and activator of transcription signaling pathway in multiple sclerosis and
ical resource of curated protein, genetic, and chemical interactions. Protein Sci the animal model of experimental autoimmune encephalomyelitis. J Interf Cytokine
2021;30:187–200. doi: 10.1002/pro.3978 . Res 2014;34:577–88. doi: 10.1089/jir.2014.0012 .
[39] Luck K, Kim DK, Lambourne L, et al. A reference map of the human binary protein
interactome. Nature 2020;580:402–8. doi: 10.1038/s41586-020-2188-x .
10